EUCTR2010-021574-11-HU进行中（未招募）不适用
A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for enrollment in this study, each of the following criteria must be satisfied with a YES answer (unless not applicable):
- •1 Subject is male or female between the ages of 18 and 75 yrs, inclusive.
- •2 If the subject is female and of childbearing potential, the subject agrees to use an acceptable form of contraception. Acceptable forms of contraception for subject or partner include condoms with spermicide gel, diaphragm with spermicide gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depot progesterone injections, and abstinence.
- •3 Subject has CABP requiring hospitalization with a PORT score of II or greater.
- •4 Subject has 3 or more of the following clinical signs and symptoms:
- •a Cough with production of purulent sputum
- •b Dyspnea or tachypnea
- •c Chest pain
- •d Fever or hypothermia
- •i Fever is defined as body temperature >38°C (100.4°F) taken orally, >38.5°C (101.3°F) tympanically, or >39°C (102.2°F) rectally.
- •ii Hypothermia is defined as body temperature <35°C (95°F).
- •e Clinical findings of pulmonary consolidation (eg, dullness on percussion, bronchial breath sounds, or egophony)
- •5 Subject’s chest x ray shows the presence of new infiltrates in a lobar or multilobar distribution characteristic of bacterial pneumonia. Subjects with the presence of necrotizing lesions characteristic of S. aureus pneumonia are eligible for enrollment in the open-label JNJ 32729463 treatment arm for S. aureus pneumonia.
- •6 Subject is able to generate an adequate sputum specimen. An adequate sputum specimen is a specimen that has fewer than 10 squamous epithelial cells and more than 25 polymorphonuclear cells per low-power field (100× magnification). Respiratory secretions may be obtained by any of the following means:
- •a deep expectoration
- •b bronchoscopy with bronchoalveolar lavage or protected-brush sampling
- •7 Subject or legally authorized representative, is able to provide written and voluntary informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •To be eligible for this study, each of the following criteria must be satisfied with a NO answer:
- •1 Subject intubated at randomization OR subject is a candidate for enrollment into the open-label S. aureus arm and has been intubated >12 hrs prior to randomization. (This does not exclude subjects who require positive-pressure breathing, such as continuous positive airway pressure or bilevel positive airway pressure)
- •2 Subject has mild CABP with a PORT score of less than II
- •3 Subject has received any systemic antibiotics within the last 2 wks before randomization
- •PRIOR ANTIBIOTIC USE: In general, subjects who have received any prior antibiotics within the past 2 wks before randomization SHOULD NOT BE ENROLLED. However, recognizing current standards of care, if one is unable to initiate study medication infusion in an acceptable time frame, subjects are eligible for enrollment if, by standard of care, they have received a single dose of a single short acting antibiotic within 12 hrs prior to randomization
- •4 Subject has received ceftriaxone, azithromycin, any fluoroquinolone or doxycycline (these are not considered to be short-acting antibiotics) or any long acting antibiotic defined as an antibiotic with >8 hr plasma half-life within the last 2 wks before randomization
- •5 Subject has an infection that necessitates the use of a concomitant antibacterial agent in addition to study medication; the use of topical agents is allowed
- •6 Subject has viral, fungal, mycobacterial, or atypical pneumonia. A subject who has tested positive for influenza virus >5 days prior to study entry, who has clinically worsened, and whose chest radiograph is now consistent with a new infiltrate suspicious for bacterial pneumonia (including small necrotizing abscesses characteristic of S. aureus pneumonia) may be entered in the open-label JNJ 32729463 treatment arm for S. aureus pneumonia
- •7 Subject has pneumonia suspected to be secondary to aspiration
- •8 Subject has primary, solitary lung abscess. Small, multiple, necrotizing abscesses suspicious for S. aureus pneumonia may be entered into the open-label JNJ 32729463 treatment arm for S. aureus pneumonia
- •9 Subject has healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia or subject has been hospitalized for greater than 72 hrs for any reason 30 days before randomization (excluding the 24 hr period before enrollment)
- •10 Subject has known bronchial obstruction or a history of postobstructive pneumonia. (This does not exclude subjects who have COPD)
- •11 Subject has primary lung cancer or another malignancy metastatic to the lungs
- •12 Subject is receiving or has received chemotherapeutic agents within the past 3 mths
- •13 Subject has cystic fibrosis, known or suspected Pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis
- •14 In the past 4 wks before randomization, the subject has shown clinically significant disease of immune function (eg, current CD4 <200, current neutrophil count <1000/µL). Subjects with human immunodeficiency virus are allowed if they have a CD4 count >200 at Baseline
- •15 Subject has received systemic steroids at a dose =10 mg/day of prednisone (or its equivalent) or other chronic immunosuppressive therapy such as disease-modifying antirheumatic drugs or interferons within the 6 weeks before Baseline. Subjects on current treatment with (or with a history of prior treatment with) inhaled steroids are not excluded from this study
研究者
相似试验
进行中（未招募）
不适用
A clinical study of the safety and effectiveness of JNJ 32729463 compared with Moxifloxacin for the treatment of patients requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP)EUCTR2010-021574-11-DEFuriex Pharmaceuticals, Inc120
尚未招募
不适用
A Randomized, Controlled, Double-blind, Multicenter Clinical Study of the Electroacupuncture Treatment on Muscle and Bone Balance of Knee OsteoarthritisKnee OsteoarthritisITMCTR2000003638Shanghai Longhua Hospital
进行中（未招募）
不适用
Evaluation of Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)Prevention of rotavirus gastroenteritis in infants and children caused by serotypes G1, G2, G3, G4, and G serotypes that contain P1A[8] (e.g., G9)EUCTR2012-001611-23-SEMerck & Co., Inc.924
进行中（未招募）
不适用
A Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq?Prevention of rotavirus gastroenteritis in infants and children caused by serotypes G1, G2, G3, G4, and G serotypes that contain P1A[8] (e.g., G9)MedDRA version: 14.1Level: LLTClassification code 10039232Term: Rotavirus gastroenteritisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-001611-23-ESMerck Sharp & Dohme Corp., una filial de Merck & Co., Inc.800
进行中（未招募）
1 期
Evaluation of Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)EUCTR2012-001611-23-CZMerck & Co., Inc.924